Jefferies Financial Group Inc. Takes $3.49 Million Position in KalVista Pharmaceuticals, Inc. $KALV

Jefferies Financial Group Inc. purchased a new position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 286,875 shares of the specialty pharmaceutical company’s stock, valued at approximately $3,494,000. Jefferies Financial Group Inc. owned 0.57% of KalVista Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in KALV. BNP Paribas Financial Markets grew its stake in KalVista Pharmaceuticals by 47.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after buying an additional 1,292 shares during the last quarter. Wolverine Asset Management LLC bought a new stake in KalVista Pharmaceuticals in the third quarter valued at $57,000. KLP Kapitalforvaltning AS acquired a new position in shares of KalVista Pharmaceuticals during the third quarter valued at $63,000. Virtus Investment Advisers LLC acquired a new position in shares of KalVista Pharmaceuticals during the second quarter valued at $81,000. Finally, Tower Research Capital LLC TRC grew its position in shares of KalVista Pharmaceuticals by 816.8% during the second quarter. Tower Research Capital LLC TRC now owns 8,059 shares of the specialty pharmaceutical company’s stock worth $91,000 after acquiring an additional 7,180 shares during the last quarter.

Insider Buying and Selling at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CFO Brian Piekos sold 1,767 shares of the company’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $27,512.19. Following the transaction, the chief financial officer owned 13,762 shares of the company’s stock, valued at approximately $214,274.34. This represents a 11.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Benjamin L. Palleiko sold 6,693 shares of the stock in a transaction on Monday, March 9th. The shares were sold at an average price of $16.08, for a total value of $107,623.44. Following the sale, the chief executive officer owned 451,815 shares of the company’s stock, valued at $7,265,185.20. This trade represents a 1.46% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 33,378 shares of company stock valued at $522,290. 4.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. TD Cowen reaffirmed a “buy” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, December 3rd. Wall Street Zen upgraded shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, December 6th. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Thursday, January 22nd. HC Wainwright lifted their price target on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a report on Friday, January 9th. Finally, Needham & Company LLC boosted their price objective on KalVista Pharmaceuticals from $28.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $29.40.

KalVista Pharmaceuticals Stock Performance

NASDAQ:KALV opened at $18.44 on Wednesday. The company has a 50-day moving average of $15.66 and a 200-day moving average of $14.19. The firm has a market cap of $932.14 million, a price-to-earnings ratio of -4.67 and a beta of -0.35. The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18. KalVista Pharmaceuticals, Inc. has a twelve month low of $9.23 and a twelve month high of $19.00.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.